• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • English
    • Français
  • Canada
    • Sandoz Site Directory
Sandoz : A Novartis Division
  • Our Work
    • What We Do
    • Quality Generics
    • Biopharmaceuticals
    • Specialty Products
  • About Us
    • Who We Are
    • Corporate Responsibility
    • Doing Business Responsibly
    • Contact Us
    • Grants, Donations and Sponsorships
  • Products
    • Consumers
    • Patients
    • Healthcare Professionals
    • Patient Support Programs
  • News
    • Media Releases
    • Media Resource Center
    • Stay Up-To-Date
  • Careers
    • Available Positions
    • Join the Sandoz Manufacturing team in Boucherville
    • Our Benefits
    • Employee Testimonials
    • Our Values and Vision
    • Diversity & Inclusion
Search
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
  • Jump to Comments
Stories/Global Impact

Recall of Ranitidine medicines

Sep 17, 2019

Patient safety and the quality of all our products is of the utmost importance to us. For that reason, as a precautionary measure, we are recalling at pharmacy level several batches of Sandoz ranitidine film-coated tablets across a number of markets, including Canada. Ranitidine is a generic medicine that is marketed globally by several pharmaceutical companies. Therefore, other pharmaceutical companies might also initiate recalls.

Already before the recall, a precautionary release and distribution stop of all our ranitidine-containing medicines in all our markets had been ordered by Sandoz and will remain valid until further clarification. These decisions follow the confirmation that traces of N-Nitrosodimethylamine (NDMA) above levels established by Health Canada and other Health Authorities internationally have been found in batches of Sandoz ranitidine film-coated tablets. Sandoz is actively investigating the root cause.

It is important that the medication be not discontinued without consulting the prescribing physician to ensure continuous treatment of the underlying disease for which the product was prescribed. Further availability of this key medicinal product for patients is a top priority for us and we are exploring possible options with Health Canada to cover patient needs.

 

    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Global Impact

Sandoz Canada completes its 5th biosimilar launch with new biosimilar Hyrimoz® (adalimumab)

Global Impact

Sandoz Canada launches the first generic versions of two original drugs: PrSandoz® Posaconazole and PrSandoz® Silodosin

Global Impact

2021 Top Employer Canada

You are here

  1. Home ›
  2. Global Impact ›

Sandoz Canada

  • Our Work
  • About Us
  • Products
  • News
  • Careers
  • Contact Us
  • Office Locations
  • Stay up to date

Subscribe to Sandoz

  • Facebook
  • Twitter
  • YouTube
  • LinkedIn
  • RSS
  • Sandoz Site Directory
© 2021 Sandoz AG

This site is intended for an audience in Canada

  • Terms of Use
  • Privacy Policy
  • Terms of Trade
  • Return Policy